BioSpace News Archive

Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced financial results for the second quarter ended June 30, 2022 and provided a business update.

iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, reported financial results for the second quarter ended June 30, 2022 and provided corporate highlights.

Femasys Inc. (NASDAQ: FEMY), today announced financial results for the second quarter and six months ended June 30, 2022 and provided a corporate update.

Yield10 Bioscience, Inc., an agricultural bioscience company, reported financial results for the three and six months ended June 30, 2022.

Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today reported financial results and provided a corporate update for the second quarter ended June 30, 2022.

NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced its financial results for the second quarter ended June 30, 2022.

NightHawk Biosciences, a fully-integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, provided strategic, financial, and operational updates for the second quarter ended June 30, 2022.

Scientists at City of Hope, one of the largest cancer research and treatment organizations in the United States, may have developed a novel blood test that can be used to detect early-onset colorectal cancer, which has been on the rise in younger adults in recent years.

The global Artificial Intelligence (Ai) In Medical Diagnostics market for the historical period of 2021 and the forecast period from 2020 to 2030, the global Artificial Intelligence (Ai) In Medical Diagnostics market was valued at US$ 2.4 million in 2021 and is projected to cross US$ 10.9 Bn by 2030, expanding at a CAGR of 37.2% from 2022 to 2030.

Genmab Announces Financial Results for the First Half of 2022.